

Review Article

The Interleukin-1 Family: A Key Regulator in the Pathogenesis of Psoriasis

Yelin Wu, Hongquan Li, Ziwei Jiang and Yuping Lai*

School of Life Science, East China Normal University, China

*Corresponding author: Yuping Lai, Shanghai Key Laboratory of Regulatory Biology, School of Life Science, East China Normal University, 500 MinhangDongChuan Road, Shanghai, 200241, China. Tel: 862154342908. Fax: 862154342908. Email: yplai@bio.ecnu.edu.cn

Received: August 15, 2014; Accepted: November 14, 2014; Published: November 17, 2014

Abstract

Interleukin-1 (IL-1) family members, as most potent molecules of the innate immune system, are key regulators of multiple inflammatory diseases. The family includes seven ligands with agonist activity (IL-1 α and IL-1 β , IL-18, IL-33, IL-36 α , IL-36 β , IL-36 γ), three receptor antagonists (IL-1Ra, IL-36Ra, IL-38), and one anti-inflammatory cytokine (IL-37). Most of these cytokines are abundantly expressed in skin under the regulation of IL-17 and act on innate immune cells to influence their survival and function. This review provides an overview of all the members of the IL-1 family and its potential regulatory roles in the pathogenesis of psoriasis.

Keywords: IL-1 family; IL-17; IL-17/IL-1 axis; Psoriasis

Introduction

Interleukin-1(IL-1) family members, as the central mediator of innate immunity and inflammation, play a key role in the biology of multiple inflammatory diseases. So far, 11 members of the IL-1 family have been identified, including seven ligands with agonist activity (IL-1 α and IL-1 β , IL-18, IL-33, IL-36 α , IL-36 β , IL-36 γ), three receptor antagonists (IL-1Ra, IL-36Ra, IL-38), and one anti-inflammatory cytokine (IL-37) (Table 1). According to the length of their precursor and the propiece for each precursor, the IL-1 family can also be categorized into three subfamilies including IL-1, IL-36 and IL-18. IL-1 family members signal through a group of closely related receptor complexes: IL-1R1 and IL-1RAcP complex as IL-1 α / β receptor, ST2 and IL-1RAcP complex as IL-33 receptor, IL-18Ra and IL-18R β complex as IL-18 receptor, and IL-1Rrp2 and IL-1RAcP complex as IL-36 receptor. The activation of these receptor complexes initiates and/or amplifies innate immune responses. Three other IL-1 receptor family members are IL-1R2, IL18BP and SIGIRR (also known as TIR8), which all act as negative regulators of IL-1 signaling [1,2].

Psoriasis is a common chronic inflammatory skin disease characterized by hyperplasia of epidermal keratinocytes and infiltrating immune cells. It is considered as a mixed Th1 and

Th17 cell-mediated immune disease. Increasing evidence from experimental and clinical findings points to the important function of IL-1 family and IL-17 in the pathogenesis of psoriasis [3-8]. Most of IL-1 family members have been reported constitutively expressed by keratinocytes *in vivo* and shown to be highly expressed in the psoriatic skin [9-12]. This increasing expression of IL-1 family members contributes to Th17 cell development, leading to the production of IL-17 [13,14]. Therefore, IL-1 family is considered as an important mediator in the initiation and maintenance of psoriatic plaques. However, not only IL-1 family induces Th17 cells to produce IL-17, IL-17 in turn can act on keratinocytes to produce more IL-1 family cytokines [15,16]. These observations thereby indicate that the IL-17/IL-1 axis plays important roles in the pathogenesis of psoriasis. In this review, we summarize the experimental and clinical findings to consolidate our understanding on the function of IL-1 family members in psoriasis.

IL-1 Family and Psoriasis

IL-1 subfamily

IL-1 α and IL-1 β : IL-1 α (IL-1F1) and IL-1 β (IL-1F2) are the first two members of IL-1 family discovered. Despite their identical activities, IL-1 α and IL-1 β have several differences. Firstly, IL-1 β is secreted and circulates systemically, whereas IL-1 α is generally

Table 1: Nomenclature and main functions of IL-1 family members in psoriasis.

Subfamily	Family member	Receptor(co-receptor)	Expression in lesional skin of psoriasis	Function in psoriasis	Whether induced by IL-17
IL-1 subfamily	IL-1 α (IL-1F1)	IL-1R1(IL-1RAcP)	Low	Proinflammatory	Yes
	IL-1 β (IL-1F2)	IL-1R1(IL-1RAcP)	High	Proinflammatory	Yes
	IL-1Ra(IL-1F3)	IL-1R1	No change	Antagonist for IL-1 α , IL-1 β	Unknown
	IL-33(IL-1F11)	ST2(IL-1RAcP)	High	Proinflammatory	Yes
IL-36 subfamily	IL-36 α (IL-1F6)	IL-1Rrp2(IL-1RAcP)	High	Proinflammatory	Yes
	IL-36 β (IL-1F8)	IL-1Rrp2(IL-1RAcP)	High	Proinflammatory	Yes
	IL-36 γ (IL-1F9)	IL-1Rrp2(IL-1RAcP)	High	Proinflammatory	Yes
	IL-36Ra(IL-1F5)	IL-1Rrp2	High	Antagonist for IL-36 α , IL-36 β , IL-36 γ	Unknown
	IL-38(IL-1F10)	IL-1Rrp2 (IL-36R)	High	Antagonist for IL-36 α , IL-36 β , IL-36 γ	Unknown
IL-18 subfamily	IL-18(IL-1F4)	IL-18Ra(IL-18R β)	Unknown	Unknown	Unknown
	IL-37(IL-1F7)	IL-18Ra	Unknown	Anti-inflammatory	Unknown

associated with the plasma membrane of the producing cell and so acts locally. Secondly, IL-1 β is mainly produced by monocytes and macrophages, whereas IL-1 α is highly expressed by keratinocytes and endothelial cells. Thirdly, the two genes are differentially regulated during development and have different contributions during immune responses. Lastly, the pro-domain of IL-1 α but not IL-1 β has a nuclear localization sequence [17]. Although IL-1 α and IL-1 β have these differences, both of them bind to the same receptor complex including IL-1R1 and IL-1RAcP, and signal through myeloid differentiation primary response protein (MyD88). While this signaling can be negatively regulated by IL-1 receptor antagonist, IL-1Ra (IL-1F3), which is the natural antagonist of IL-1 α and IL-1 β [18].

In skin lesions of psoriasis patients, IL-1 β has been shown to be markedly increased, and effective treatment of psoriasis led to a significant decrease in epidermal IL-1 β expression, suggesting that IL-1 subfamily plays a role in the pathogenesis of psoriasis [10,12]. Moreover, IL-17 was markedly increased in lesional skin of psoriasis patients, and these patients treated with Secukinumab, a fully human anti-IL-17A monoclonal antibody, had a reduction of 75% or more in the Psoriasis Area-and-Severity Index score (PASI75) [19-21]. However, it was not clear whether IL-17 regulated IL-1 expression in these studies. In 2013, the studies from Albanesi's and Chen's groups showed that IL-17A induced IL-1 β expression in macrophages via the activation of MAPKs, NF- κ B and AP-1 [22], and IL-17, in combination of IL-4, markedly increased IL-1 α and IL-1Ra in supernatants and cell lysates of cultured keratinocytes [16], while the studies from Cooper's and Mee's groups showed decreased IL-1 α but increased IL-1 β expression in lesional skin of psoriasis patients [23,24]. Moreover, when Muhr et al. compared IL-1 subfamily gene expression in keratinocytes from psoriasis patients and healthy individuals in the presence of IL-17, they found that IL-17 induced IL-1 β but not IL-1 α and IL-1Ra expression in keratinocytes from healthy individuals [15]. Therefore, how IL-17 specifically regulates the expression of IL-1 subfamily members in psoriasis needs further investigation.

To confirm the role of IL-1 α , IL-1 β and IL-1Ra in the pathogenesis of psoriasis *in vivo*, transgenic mice targeting related genes were generated. Skin lesions with hyper proliferative epidermis and increased antimicrobial transcripts including S100A7, S100A9, DEFB4 were observed in *Il1a* and *Il1rn* transgenic mice, suggesting IL-1 α signaling enables to initiate an inflammatory reaction in psoriatic development [25,26]. In addition, the deficiency of IL-1Ra in mice resulted in spontaneous psoriatic-like lesions [27]. In human, children born with a genetic deficiency of Interleukin-1-Receptor Antagonist (IL-1RA) or functional inactive IL-1RA suffer from severe systemic and local inflammation, including pustular skin eruption [28,29]. Moreover, the profile of the transcriptome from psoriatic tissue and IL-1 α -treated cultured human keratinocytes revealed a high correlation of the transcriptome profile between IL-1 α -treated keratinocytes and psoriatic tissues, suggesting the inflammatory milieu in the epidermal microenvironment in psoriasis is more likely dependent on evolutionarily ancient cytokines such as IL-1 α , rather than those of the adaptive immune response [30]. Furthermore, IL-1 β , as well as IFN- γ , was able to induce the psoriatic regenerative epidermal phenotype including keratin16, keratin17, and keratinocyte Transglutaminase (TGK), ICAM-1 and HLA-DR in both normal

human skin and non-lesional skin from psoriatic patients, and IL-1Ra inhibited the effects of IFN- γ on the expression of keratin 17 and TGK in normal skin but not in non-lesional skin of patients with psoriasis, suggesting IL-1Ra system may be dysregulated in psoriatic skin [31]. However, whether IL-1 β acts directly or indirectly to these target genes remains unclear. Altogether, these findings demonstrate the tremendous impact of IL-1 subfamily members on psoriasis, and suggest that the blockage of IL-1 signaling might have a broader clinical impact on psoriasis.

IL-33

IL-33(IL-1F11) is the most recently identified member of the IL-1 family and is a ligand for the orphan receptor ST2 [32]. In contrast to other IL-1 family members, it is not typically expressed by haematopoietic cells but is abundantly expressed in the endothelial cells and keratinocytes. In psoriasis patients, both IL-33 and ST2 significantly increased in lesional and non-lesional skin, compared to those in healthy skin [33-36]. The studies from Balato's and Theoharides's groups showed that IL-33 was strongly associated with endothelial cells in psoriatic skin compared to non-lesional psoriatic skin and healthy controls [33,36]. Moreover, IL-33 was secreted by psoriatic keratinocytes and was present in nucleus as well as cytoplasm in keratinocytes [33]. The expression of IL-33 was partially under the regulation of IL-17A. The study from Meehphansan's group showed that IL-17A induced IL-33 expression at mRNA and protein levels in time and dose-dependent manners in Normal Human Epidermal Keratinocytes (NHEKs). This induction was via the activation of EGFR, ERK, p38 and STAT3, as IL-17A-induced IL-33 expression was blocked by the addition of EGFR, ERK, p38 and STAT3 inhibitors [35]. However, an intrinsic mechanism by which IL-17 regulates IL-33 expression in keratinocytes warrants further investigation.

IL-33, as a dual function protein, acts as both a cytokine to activate a number of immune cells with potent pro-inflammatory effects and intracellular nuclear factor to suppress pro-inflammatory gene transcription [37,38]. IL-33 induces mast cell degranulation, maturation and the production of IL-1, IL-6, IL-13, TNF- α , CCL2 and CCL3 in psoriatic lesional skin [39,40]. In 2010, a relationship between IL-33 and peptide Substance P (SP), VEGF in mast cell was well studied. IL-33 augmented the effect of SP on inducing mast cell release of VEGF, leading to increased angiogenesis in psoriasis [36]. Our previous data showed that IL-17 induced REG3A to regulate keratinocyte hyperproliferation in psoriasis [41], and the induction of REG3A by IL-17 was dependent on IL-33(unpublished data). These results thereby demonstrate the important role of IL-33 in psoriasis-like plaque formation and targeting IL-33 may provide a new treatment strategy for psoriasis.

IL-36 subfamily

IL-36 proteins: IL-36 proteins contain IL-36 ligands and IL-36Ra. IL-36 ligands include IL-36 α , IL-36 β and IL-36 γ (formerly IL-1F6, IL-1F8 and IL-1F9) that signal through the IL-1 receptor family members such as IL-1Rrp2 (IL-1RL2) and IL-1RAcP [42-44]. IL-36Ra (IL-1F5) is an antagonist of IL-36 signaling. IL-36Ra binds to IL-1Rrp2, blocks IL-36 ligand binding to the IL-1Rrp2 receptor and the subsequent recruitment of IL-1RAcP [45].

IL-36 is abundantly expressed in skin and a few other tissues. Their expression can be strongly induced in monocytes and keratinocytes

[2]. Accumulating evidence suggests that IL-36 is a crucial cytokine in the pathogenesis of psoriasis [11,42,43,46]. In 2001, Debets et al. first reported that IL-36 proteins were over expressed in psoriatic lesional skin [43]. This observation was further confirmed by other scientists. Johnston's group showed IL-36Ra (IL-1F5), IL-36 α (IL-1F6), IL-36 β (IL-1F8), IL-36 γ (IL-1F9) were significantly higher in psoriatic lesional skin than those in non-lesional skin [11]. Blumberg et al. also found increased expression of IL-1Rrp2, IL-36Ra and IL-36 α in human psoriatic skin [42]. Moreover, IL-36 has been shown to be under the regulation of IL-17. Carrier's study reported that IL-36 cytokines were increased in a Th17-dominant psoriasis-like animal model [47]. Muhr's study showed that IL-17 induced IL-1 family members IL-36 α and IL-36 γ , but not anti-inflammatory members IL-1Ra, IL-36Ra and IL-37 in keratinocytes from psoriatic skin, when compared to those from healthy individuals [15].

To confirm the pathological role of IL-36 proteins in psoriasis development, IL-36 α transgenic mouse was generated by Blumberg's group. The mouse exhibited psoriatic skin phenotype with thickened scaly skin, acanthosis, hyperkeratosis and a mixed inflammatory cell infiltrate in the dermis [42]. Cytokines implicated in the pathogenesis of psoriasis, such as IL-23, IL-17 and TNF- α , were increased in this model, and they were induced in wild-type mouse skin by IL-36 α and in turn induced IL-36 α production in keratinocytes. The combination of IL-36 α transgene with an IL-36Ra deficiency resulted in the exacerbation of the psoriatic phenotype, demonstrating the antagonistic activity of IL-36Ra *in vivo* [42]. Moreover, the psoriatic phenotypes were ameliorated after IL-36 α transgenic mice crossed with IL-36Ra transgenic mice. In summary, dysregulated expression of IL-36 agonists and antagonists promotes cutaneous inflammation, leading to psoriatic inflammatory skin disorders.

Increasing evidence further dissects the roles of IL-36 proteins in the pathogenesis of psoriasis. Towne's group reported that IL-36 α , IL-36 β and IL-36 γ activated IL-8 promoter and induced IL-6 secretion through the MAPKs, JNK and ERK1/2 pathway [44]. Microarray analysis was performed by Johnston's group after reconstituted epidermal cultures treated with recombinant IL-36 α , IL-36 β and IL-36 γ . Strikingly, these cytokines not only induced IL-8 expression but also induced the expression of Antimicrobial Peptides (AMPs), Matrix Metalloproteinase's (MMPs) and growth factors. In particular, IL-36 β effectively induced HBD-2, HBD-3, MMP19 and MMP9 [11]. IL-36 α and IL-36 β but not IL-36 γ directly induced TNF- α , IL-6, IL-8, hBD2, S100A7, and these effects of IL-36 α and IL-36 β were synergized with IL-17A and TNF- α [47]. In addition to keratinocytes, IL-36 subfamily has also been reported to target another cell types such as dendritic cells, as IL-36 receptor is expressed in this cell type [48-50]. In Bone Marrow-Derived Dendritic Cells (BMDCs), IL-36 induced the expression of IL-12, IL-1 β , IL-6, TNF- α and IL-23. In addition, IL-36 β enhanced the expression of CD80, CD86 and MHC class II by BMDCs [50]. Besides BMDCs, IL-36 induced the expression of IFN- γ , IL-4 and IL-17 in CD4+ T cells, suggesting a critical role of IL-36 subfamily members in the stimulation of T helper cell responses [50].

Moreover, a link between IL-36Ra and Generalized Pustular Psoriasis (GPP), a different form of psoriasis, has been identified [51-53]. Marrakchi et al. performed homozygosity mapping and direct sequencing in nine Tunisian multiplex families with autosomal

recessive GPP and found that familial GPP was caused by the deficiency of IL-36Ra, that is, all the patients with GPP were found to carry a loss function mutation in *IL-36RN*. This aberrant IL-36Ra structure and function led to deregulated secretion of inflammatory cytokines (IL-1 α , IL-6, IL-8, TNF- α) [51]. In 2013, Sugiura et al. reported that the majority of cases of GPP without a history of psoriasis vulgaris were caused by homozygous or compound heterozygous mutations of *IL36RN*, although only a few cases of GPP preceded or accompanied by psoriasis vulgar were found to have *IL36RN* mutations [52]. In 2014, a case of GPP was successfully treated by Granulocyte and Monocyte Adsorption apheresis (GMA), suggesting that granulocytes/monocytes play a major role in the immunopathogenesis of GPP caused by deficiency of IL-36Ra [53].

IL-38

IL-38(IL-F10) is originally identified in silicon. Its gene is located in the IL-1 family cluster on chromosome 2 next to the genes encoding IL-1R1 and IL-36Ra [1,54]. As one of three IL-1 family receptor antagonists, IL-38 shares 43% homology with IL-36Ra [54]. It binds to the IL-36R to inhibit IL-36 signaling as IL-36Ra does [55]. IL-38 polymorphism is associated with psoriatic arthritis, suggesting IL-38 might play a role in the pathogenesis of this inflammatory skin disease [56-58]. However, until now, no study reports that IL-38 is regulated by IL-17A. Conversely, addition of IL-38 in peripheral blood mononuclear cells inhibited the production of IL-22 and IL-17A, suggesting IL-38 may be involved in the regulation of IL-17 expression [55].

IL-18 subfamily: IL-18 and IL-37

IL-18(IL-1F4) and IL-37(IL-1F7) are expressed by macrophages and dendritic cells as well as epithelial cells, such as keratinocytes. Both IL-18 and IL-37 bind to the same receptor IL-18Ra. However, IL-18 acts as a proinflammatory factor, while IL-37 serves as a natural brake of inflammation. There is no direct evidence support that IL-17 induces the expression of IL-18 and IL-37, but it is reported that IL-18 was decreased in cuprizone-treated Act1 knockout mice compared to that in WT mice, indicating the essential role of IL-17-Act1-mediated signaling in the production of IL-18 [59]. More importantly, IL-18 has also been implicated in several autoimmune diseases such as psoriasis. Arican et al reported IL-18 expression was increased in the serum of psoriatic patients and correlated with disease severity [60]. However, so far no report shows that IL-37 is correlated with the pathogenesis of psoriasis.

Conclusions and Perspectives

Psoriasis is a common immune-mediated inflammatory disease. The pathogenesis of psoriasis is a complex integration of genetic, immunological and environmental components [8]. IL-17/IL-1 axis exerts a proinflammatory effect on keratinocytes and immune cells in psoriasis. IL-17 secreted by Th17 cells and $\gamma\delta$ T cells induces keratinocyte activation with the release of the proinflammatory cytokines such as IL-1 family members. IL-1, in turn, can act on T cells and induce Th17 cells differentiation from naïve precursors, as well as in the promotion of IL-17- and IL-22- producing T cells. These events sustain and amplify the chronic inflammation in psoriasis (Figure 1). Moreover, cytokines of IL-1 family induce the production of multiple antimicrobial peptides or proteins in keratinocytes, leading to hyperproliferation of skin epidermis. So far, biological

27. Shepherd J, Little MC, Nicklin MJ. Psoriasis-like cutaneous inflammation in mice lacking interleukin-1 receptor antagonist. *J Invest Dermatol.* 2004; 122: 665-669.
28. Aksentijevich I, Masters SL, Ferguson PJ, Dancy P, Frenkel J, van Royen-Kerkhoff A, et al. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. *N Engl J Med.* 2009; 360: 2426-2437.
29. Reddy S, Jia S, Geoffrey R, Lorier R, Suchi M, Broeckel U, et al. An autoinflammatory disease due to homozygous deletion of the IL1RN locus. *N Engl J Med.* 2009; 360: 2438-2444.
30. Mee JB, Johnson CM, Morar N, Burslem F, Groves RW. The psoriatic transcriptome closely resembles that induced by interleukin-1 in cultured keratinocytes: dominance of innate immune responses in psoriasis. *Am J Pathol.* 2007; 171:32-42.
31. Wei L, Debets R, Hegmans JJ, Benner R, Prens EP. IL-1 beta and IFN-gamma induce the regenerative epidermal phenotype of psoriasis in the transwell skin organ culture system. IFN-gamma up-regulates the expression of keratin 17 and keratinocyte transglutaminase via endogenous IL-1 production. *J Pathol.* 1999; 187:358-364.
32. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. *Immunity.* 2005; 23: 479-490.
33. Balato A, Lembo S, Mattii M, Schiattarella M, Marino R, De Paulis A, et al. IL-33 is secreted by psoriatic keratinocytes and induces pro-inflammatory cytokines via keratinocyte and mast cell activation. *Exp Dermatol.* 2012; 21: 892-894.
34. Hueber AJ, Alves-Filho JC, Asquith DL, Michels C, Millar NL, Reilly JH, et al. IL-33 induces skin inflammation with mast cell and neutrophil activation. *Eur J Immunol.* 2011; 41: 2229-2237.
35. Meephansan J, Komine M, Tsuda H, Karakawa M, Tominaga S, Ohtsuki M. Expression of IL-33 in the epidermis: The mechanism of induction by IL-17. *J Dermatol Sci.* 2013; 71: 107-114.
36. Theoharides TC, Zhang B, Kempuraj D, Tagen M, Vasiadi M, Angelidou A, et al. IL-33 augments substance P-induced VEGF secretion from human mast cells and is increased in psoriatic skin. *Proc Natl Acad Sci USA.* 2010; 107: 4448-4453.
37. Haraldsen G, Balogh J, Pollheimer J, Sponheim J, Kuchler AM. Interleukin-33 - cytokine of dual function or novel alarmin? *Trends Immunol.* 2009; 30: 227-233.
38. Ali S, Mohs A, Thomas M, Klare J, Ross R, Schmitz ML, et al. The dual function cytokine IL-33 interacts with the transcription factor NF- κ B to dampen NF- κ B-stimulated gene transcription. *J Immunol.* 2011; 187: 1609-1616.
39. Allakhverdi Z, Smith DE, Comeau MR, Delespesse G. Cutting edge: The ST2 ligand IL-33 potently activates and drives maturation of human mast cells. *J Immunol.* 2007; 179: 2051-2054.
40. Iikura M, Suto H, Kajiwara N, Oboki K, Ohno T, Okayama Y, et al. IL-33 can promote survival, adhesion and cytokine production in human mast cells. *Lab Invest.* 2007; 87: 971-978.
41. Lai Y, Li D, Li C, Muehleisen B, Radek KA, Park HJ, et al. The antimicrobial protein REG3A regulates keratinocyte proliferation and differentiation after skin injury. *Immunity.* 2012; 37: 74-84.
42. Blumberg H, Dinh H, Trueblood ES, Pretorius J, Kugler D, Weng N, et al. Opposing activities of two novel members of the IL-1 ligand family regulate skin inflammation. *J Exp Med.* 2007; 204: 2603-2614.
43. Debets R, Timans JC, Homey B, Zurawski S, Sana TR, Lo S, et al. Two novel IL-1 family members, IL-1 delta and IL-1 epsilon, function as an antagonist and agonist of NF-kappa B activation through the orphan IL-1 receptor-related protein 2. *J Immunol.* 2001; 167:1440-1446.
44. Towne JE, Garka KE, Renshaw BR, Virca GD, Sims JE. Interleukin (IL)-1F6, IL-1F8, and IL-1F9 signal through IL-1Rrp2 and IL-1RAcP to activate the pathway leading to NF-kappaB and MAPKs. *J Biol Chem.* 2004; 279: 13677-13688.
45. Towne JE, Renshaw BR, Douangpanya J, Lipsky BP, Shen M, Gabel CA, et al. Interleukin-36 (IL-36) ligands require processing for full agonist (IL-36 β , IL-36 δ , and IL-36 η) or antagonist (IL-36Ra) activity. *J Biol Chem.* 2011; 286: 42594-42602.
46. Blumberg H, Dinh H, Dean C, Trueblood ES, Bailey K, Shows D, et al. IL-1RIL2 and its ligands contribute to the cytokine network in psoriasis. *J Immunol.* 2010; 185: 4354-4362.
47. Carrier Y, Ma HL, Ramon HE, Napierata L, Small C, O'Toole M, et al. Inter-regulation of Th17 cytokines and the IL-36 cytokines *in vitro* and *in vivo*: implications in psoriasis pathogenesis. *J Invest Dermatol.* 2011; 131: 2428-2437.
48. Ramadas RA, Ewart SL, Iwakura Y, Medoff BD, LeVine AM. IL-36 β exerts pro-inflammatory effects in the lungs of mice. *PLoS One.* 2012; 7: 45784.
49. Vigne S, Palmer G, Martin P, Lamacchia C, Strebel D, Rodriguez E, et al. IL-36 signaling amplifies Th1 responses by enhancing proliferation and Th1 polarization of naive CD4+ T cells. *Blood.* 2012; 120: 3478-3487.
50. Vigne S, Palmer G, Lamacchia C, Martin P, Talabot-Ayer D, Rodriguez E, et al. IL-36R ligands are potent regulators of dendritic and T cells. *Blood.* 2011; 118: 5813-5823.
51. Marrakchi S, Guigue P, Renshaw BR, Puel A, Pei XY, Fraitag S, et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. *N Engl J Med.* 2011; 365: 620-628.
52. Sugiura K, Takemoto A, Yamaguchi M, Takahashi H, Shoda Y, Mitsuma T, et al. The majority of generalized pustular psoriasis without psoriasis vulgaris is caused by deficiency of interleukin-36 receptor antagonist. *J Invest Dermatol.* 2013; 133: 2514-2521.
53. Sugiura K, Haruna K, Suga Y, Akiyama M. Generalized pustular psoriasis caused by deficiency of interleukin-36 receptor antagonist successfully treated with granulocyte and monocyte adsorption apheresis. *J Eur Acad Dermatol Venereol.* 2014.
54. Bensen JT, Dawson PA, Mychaleckyj JC, Bowden DW. Identification of a novel human cytokine gene in the interleukin gene cluster on chromosome 2q12-14. *J Interferon Cytokine Res.* 2001; 21: 899-904.
55. van de Veerdonk FL, Stoeckman AK, Wu G, Boeckermann AN, Azam T, Netea MG, et al. IL-38 binds to the IL-36 receptor and has biological effects on immune cells similar to IL-36 receptor antagonist. *Proc Natl Acad Sci USA.* 2012; 109: 3001-3005.
56. Chou CT, Timms AE, Wei JC, Tsai WC, Wordsworth BP, Brown MA. Replication of association of IL1 gene complex members with ankylosing spondylitis in Taiwanese Chinese. *Ann Rheum Dis.* 2006; 65: 1106-1109.
57. Guo ZS, Li C, Lin ZM, Huang JX, Wei QJ, Wang XW, et al. Association of IL-1 gene complex members with ankylosing spondylitis in Chinese Han population. *Int J Immunogenet.* 2010; 37: 33-37.
58. Rahman P, Sun S, Peddle L, Snelgrove T, Melay W, Greenwood C, et al. Association between the interleukin-1 family gene cluster and psoriatic arthritis. *Arthritis Rheum.* 2006; 54: 2321-2325.
59. Kang Z, Liu L, Spangler R, Spear C, Wang C, Gulen MF, et al. IL-17-induced Act1-mediated signaling is critical for cuprizone-induced demyelination. *J Neurosci.* 2012; 32: 8284-8292.
60. Arican O, Aral M, Sasmaz S, Ciragil P. Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. *Mediators Inflamm.* 2005; 2005: 273-279.
61. Papp KA, Tyring S, Lahfa M, Prinz J, Griffiths CE, Nakanishi AM, et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. *Br J Dermatol.* 2005; 152: 1304-1312.
62. Reich K. Anti-interleukin-17 monoclonal antibody ixekizumab in psoriasis. *N Engl J Med.* 2012; 367:274- 275.
63. Papp KA, Leonardi C, Menter A, Ortonne JP, Krueger JG, Kricorian G, et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. *N Engl J Med.* 2012; 366: 1181-1189.